Forest Laboratories and Blue Ash Therapeutics Enter Into Asset Purchase Agreement for Azimilide, a Novel Phase III Antiarrhythmic Agent

Forest Laboratories, Inc. FRX today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.